17 August 2018
Visiongain’s new report Global Pharma Contract Sales Market 2017-2027: Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services indicates that the global pharma contract sales market will see $8.09bn in spending in 2021.
The global pharma contract sales market is expected to grow at a CAGR of 10.5% in the first half of the forecast period. The market is expected to grow at a CAGR of 9.5% from 2016-2027. The market is estimated at $4.9bn in 2016 and $8.09bn in 2021.
The lead analyst of the report said: “Pharma companies will increasingly look to outsource field sales to CSOs, for a wide range of reasons including for promotion for mature products with smaller marketing budgets, for product launches for smaller pharma companies, and for expertise in reaching emerging markets.
Demand for MSLs and clinical education teams has risen rapidly in recent years, driven by the launch of complex, specialty medicines for chronic diseases, as well as by increased awareness of treatment options, and choice, among patients and doctors. Outsourcing to CSOs accounted for between 10% and 20% of personal promotional spending in the leading developed markets in 2016. The rising trend in outsourcing across the whole pharma sector will benefit the contract sales market in this 10-year forecast period, as will challenges in market access, complex drug development and the increasing influence of the payer in prescribing decisions.”
The 260-page report contains 95 tables and 65 figures that add visual analysis in order to explain the developing trends within the Global Pharma Contract Sales Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments: Contract detailing (personal promotion/field sales), Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and others, Medical education services and Sample management services
This report also breaks down the revenue forecast for pharma contract sales market by therapeutic segments: Cardiovascular disease, Metabolic disorders, Cancer treatment and Other.
The 260-page report offers market forecasts for the US, Germany, UK, France, Italy, Spain, China, Japan, India, Russia, Brazil and Rest of the World. Moreover, our work discusses the leading companies in pharma contract sales.
The report Global Pharma Contract Sales Market 2017-2027: Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services report will be of value to anyone who wants to better understand the pharma contract sales market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharma contract sales market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth